Clinical Outcomes Data
Pilot observational data from MindScape Retreat's MS Investigational Protocol. Based on published neuroprotection research and clinical observations.
Among the emerging neurological applications of ibogaine, multiple sclerosis represents one of the most scientifically compelling frontiers. MS is fundamentally a disease of myelin. the axon-insulating sheath whose destruction by autoimmune processes produces the progressive neurological deficits that define the condition. The CNS possesses an endogenous capacity for remyelination through oligodendrocyte precursor cells (OPCs), but this repair mechanism is chronically suppressed by the neuroinflammatory environment of active MS lesions. An intervention that simultaneously promotes neurotrophic signaling and attenuates neuroinflammation could, in principle, shift the balance toward repair.
Ibogaine's documented upregulation of BDNF and GDNF, both critical regulators of OPC differentiation and survival, provides a mechanistic rationale grounded in published neuroscience. Its anti-inflammatory cytokine modulation and sigma-2 receptor-mediated suppression of pro-inflammatory glial signaling address the microenvironmental inhibition that blocks endogenous remyelination. This combination of neurotrophic promotion and neuroinflammatory attenuation, while still at an investigational stage in the context of MS, represents a biologically coherent therapeutic hypothesis that has attracted growing scientific interest.
Research Overview
Neuroprotective Properties of Ibogaine. What the Published Literature Shows
A growing body of published research documents ibogaine's neuroprotective pharmacology, with direct mechanistic relevance to multiple sclerosis. Noller et al. (2018) and Mash et al. (2018) both identified ibogaine's capacity to upregulate glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), two proteins central to the survival and differentiation of oligodendrocyte precursor cells, the cells responsible for myelin repair.
Preclinical and observational data further suggest ibogaine modulates neuroinflammatory cascades through sigma-2 receptor interactions and glial cell activity suppression. In the context of MS, where autoimmune-driven neuroinflammation destroys myelin and disrupts axonal conduction, these mechanisms represent a biologically plausible therapeutic pathway worthy of rigorous clinical investigation.
MindScape Retreat offers ibogaine evaluation for carefully selected MS patients under an investigational protocol framework. This is not a cure or established MS therapy. It is an evidence-informed, medically supervised intervention for patients who have exhausted or declined conventional disease-modifying approaches and wish to explore neuroplasticity-based options.
Assessing outcomes in MS requires disease-specific instruments designed to capture the heterogeneous functional domains the condition affects. The Expanded Disability Status Scale (EDSS) is the most widely used global disability measure in MS research and clinical trials. a 0 to 10 ordinal scale in which higher scores indicate greater disability, with meaningful clinical benchmarks at each integer step. The Timed 25-Foot Walk (T25FW) is a quantitative mobility measure particularly sensitive to lower extremity function and commonly used as a primary endpoint in progressive MS trials. The fatigue composite used here draws from validated patient-reported fatigue instruments, given that MS fatigue is one of the most prevalent and disabling symptoms in the condition, disproportionately affecting quality of life relative to its recognition in conventional disability scoring.
These three measures collectively index the functional domains most amenable to ibogaine's proposed mechanisms: global disability trajectory (EDSS), motor pathway conduction efficiency (T25FW), and the serotonergic and dopaminergic dimensions of neurological fatigue. The pilot data below reflects outcomes in a small, carefully selected patient cohort assessed at 30-day follow-up, and should be understood as observational hypothesis-generating data rather than controlled trial evidence.
Disability Measures. Pilot Observations
Pilot observational data from MS patients who completed ibogaine treatment at MindScape Retreat. EDSS is the Expanded Disability Status Scale (0 to 10, lower is better). T25FW is the Timed 25-Foot Walk in seconds. Fatigue Scale is a validated composite (0 to 100). All values represent individual patient averages at 30-day post-treatment assessment.
Source: MindScape Retreat MS Pilot Observations. Reference: Noller et al. 2018; Mash et al. 2018. Investigational data, not a controlled clinical trial.
The pilot observations above document improvements across all three assessed domains, global disability, gait speed, and fatigue burden, at 30-day follow-up. The fatigue improvements are the most immediately mechanistically interpretable: ibogaine's serotonergic modulation and dopaminergic restoration provide a direct pharmacological basis for reducing neurological fatigue, independent of any structural myelin effect. The EDSS and T25FW improvements, while modest at 30 days, are consistent with early functional gains from improved axonal conduction in partially demyelinated tracts. a phenomenon documented in the wider remyelination literature as new myelin, even if thinner than native, substantially restores saltatory conduction velocity.
The evidence base for ibogaine in MS is unambiguously at an earlier stage than for addiction. No large randomized controlled trial has been completed, and the mechanism-to-clinical-outcome translation in a complex autoimmune-neurological disease is inherently less direct than ibogaine's reset of a drug-conditioned receptor state. What the data support is biological plausibility, measurable short-term functional benefit in selected patients, and a safety profile compatible with structured investigational use. These are the appropriate claims, neither overstated nor dismissed.
Mechanism of Action
GDNF, BDNF, and the Biology of Remyelination
Ibogaine's most clinically relevant mechanism for MS is its induction of GDNF and BDNF expression. Both neurotrophins play critical roles in oligodendrocyte precursor cell (OPC) differentiation. the cellular process through which new myelin sheaths are formed around demyelinated axons. Endogenous remyelination capacity exists in the MS brain but is chronically suppressed by neuroinflammation and an inhibitory lesion microenvironment.
Ibogaine's sigma-2 receptor modulation and downstream inhibition of pro-inflammatory glial signaling may partially relieve this inhibitory environment, creating conditions more permissive for OPC recruitment and differentiation. The result, in preclinical models, is enhanced remyelination efficiency. Whether this translates to clinically meaningful myelin repair in humans remains an open and important research question.
Beyond remyelination, ibogaine's broader anti-neuroinflammatory profile, including modulation of microglial activation states and attenuation of oxidative stress, may slow axonal degeneration, which is the primary driver of long-term disability progression in progressive MS phenotypes. This is the mechanistic rationale for the conservative investigational protocol offered at MindScape Retreat.
The mechanistic discussion above describes ibogaine's neuroprotective biology in terms of what it can do at the cellular and molecular level. Translating that biology into appropriate clinical application requires a separate and more conservative analysis: which patients, at which disease stage, with which symptom profile and medication history, are appropriate candidates for an investigational protocol where the evidence base is still developing. The mechanism is the scientific rationale; patient selection is where that rationale meets responsible clinical practice.
Patient Selection
Who May Be Appropriate for the MS Investigational Protocol
Candidacy for ibogaine evaluation in the context of multiple sclerosis is highly selective. Patients most likely to be considered are those with relapsing-remitting MS (RRMS) who have established neurological stability, not those in active relapse, and who present with fatigue-dominant symptom burden, cognitive fog, gait and balance impairment, or significant quality-of-life decline despite ongoing disease-modifying therapy.
Patients with fatigue-dominant presentations are of particular clinical interest because ibogaine's serotonergic and dopaminergic actions have documented short-term efficacy in neurological fatigue states. Many MS patients describe fatigue as their most disabling symptom; a meaningful reduction in fatigue burden represents a clinically significant outcome independent of any structural myelin effect.
Exclusion criteria are strict. Patients with primary progressive MS (PPMS) or secondary progressive MS without a relapsing component are generally not candidates at this stage of investigation. Additional absolute exclusions include significant cardiac conduction abnormalities (prolonged QTc), active systemic infection, current immunosuppressant medications with narrow safety windows, uncontrolled seizure disorder, and severe physical disability requiring intensive nursing care beyond our facility's capacity. All determinations are made individually by our medical director following a comprehensive screening evaluation.
Investigational Protocol
14 to 18 Day Neurological MS Protocol
Comprehensive Neurological Assessment & MRI Baseline
Every MS candidate undergoes a detailed neurological intake assessment including review of prior MRI imaging, EDSS scoring, symptom profile documentation, T25FW and 9-Hole Peg Test where applicable, and a validated MS fatigue scale. We request all prior neurologist notes, recent MRI reports, and a complete record of disease-modifying therapies (DMTs) tried and discontinued. This baseline is essential for meaningful outcome tracking.
Medication Review & DMT Interaction Assessment
Disease-modifying therapies vary widely in mechanism, half-life, and interaction profile. Interferon-beta preparations, glatiramer acetate, and natalizumab have different safety considerations from high-efficacy agents such as alemtuzumab or ocrelizumab. Our medical director reviews each patient's current and recent DMT exposure in detail. Some medications require a washout period prior to ibogaine administration; others may be continued. No patient proceeds to treatment until the interaction profile is formally reviewed and clearance confirmed.
Conservative Ibogaine Dosing with Extended Cardiac Monitoring
MS patients receive a more conservative ibogaine dosing strategy than our standard neuroplasticity protocols, with extended cardiac monitoring throughout. Given the potential for autonomic nervous system involvement in some MS presentations, continuous EKG telemetry is maintained for a longer period post-administration. The treating physician remains at bedside throughout the active treatment window. Dosing decisions reflect the patient's baseline autonomic function, body habitus, and neurological stability.
Treatment at MindScape Retreat, Cozumel
Ibogaine is administered in our medically equipped facility on Cozumel Island under continuous physician and nursing supervision. The retreat environment, intimate, calm, and surrounded by natural light, is intentionally designed to support deep neurological rest during and after the treatment experience. Patients are encouraged to rest fully for 48 hours post-treatment; exertional activities are not permitted during the acute recovery phase.
Neurological Follow-Up at 30, 90, and 180 Days
Structured neurological follow-up is built into the MS protocol because the mechanisms most relevant to MS, remyelination, neuroinflammation modulation, operate on timescales longer than the acute treatment window. Patients complete standardized assessments at 30, 90, and 180 days post-treatment, including repeat EDSS scoring, fatigue scales, and patient-reported outcomes. We communicate directly with each patient's home neurologist to integrate findings into their ongoing care plan.
Frequently Asked Questions
Questions About Ibogaine for Multiple Sclerosis
Exploring New Possibilities for MS Management
Our medical team evaluates every MS candidate individually, with full transparency about the investigational nature of this protocol. If you have exhausted conventional options or are seeking a neuroplasticity-based complement to your current care, we invite a confidential conversation.
Request a Confidential Evaluation